This activity is supported by an independent educational grant from Milestone
Pharmaceuticals.
2) Our expert faculty from here at #ACC25 is Narendra Singh MD @heartdrsingh, #cardiologist & faculty at both @MCG_AUG and College of Health Professions, Mercer University Atlanta. He is Director, Clinical Research at NSC Cardiology, Johns Creek, Georgia. pic.twitter.com/5PfMr7HEsD
— cardio-met (@cardiomet_CE) March 30, 2025
4a) Hey—you’ve learned on this @cardiomet_ce feed before about a novel approach to PSVT. Yes, we have introduced you to #etripamil–a still-investigational #CCB administered via the 👃, representing the first advance in self-administered SVT treatment in many years! pic.twitter.com/1ciCmi5YE7
— cardio-met (@cardiomet_CE) March 30, 2025
4c) Non-dihydropyridine #CCBs (verapamil, diltiazem) are preferred over #dihydropyridine #CCBs (amlodipine, nifedipine) for #PSVT because
— cardio-met (@cardiomet_CE) March 30, 2025
a. DHPs more likely cause #vasodilation
b. non-DHPs slow conduction through #AV node
c. DHPs have greater effect on contractility
d. a+b
6) Prior trials
— cardio-met (@cardiomet_CE) March 30, 2025
🔓 https://t.co/e6dkHx8qqg
➡️ 70mg #etripamil, or a regimen using a repeat-dose if persistent sx 10 min after the first, self-administered outside the healthcare setting, converted #PSVT to #SR to a significant degree by 30 min. This was #NODE_301. pic.twitter.com/7UPoUM2I4m
7b) 109/181 (60.2%) of #PSVT episodes converted to #SR w/self- administered #etripamil within 30min as did 75.1% w/in 60min.
— cardio-met (@cardiomet_CE) March 30, 2025
21/26 (81%) pts whose PSVT was successfully terminated with etripamil during their 1st episode, also had success with etripamil during their 2nd episode.
8a) In the #RAPID trial, 🔓 https://t.co/wzyNGUy0jl, the conversion efficacy of #etripamil vs placebo was 64% vs 31% (p<0.001) with a median time-to-conversion of 17.2 min vs 53.5 min, respectively. pic.twitter.com/urRq9ld72f
— cardio-met (@cardiomet_CE) March 30, 2025
8a) In the #RAPID trial, 🔓 https://t.co/wzyNGUy0jl, the conversion efficacy of #etripamil vs placebo was 64% vs 31% (p<0.001) with a median time-to-conversion of 17.2 min vs 53.5 min, respectively. pic.twitter.com/urRq9ld72f
— cardio-met (@cardiomet_CE) March 30, 2025
8c) . . . that self-administered intranasal etripamil without direct medical supervision or a test dose prior to first use is safe and effective in patients with multiple episodes of SVT. This was the #NODE_303 study.
— cardio-met (@cardiomet_CE) March 30, 2025
See 🔓https://t.co/84ZI98IOBj pic.twitter.com/xB1ch9ugLb
10a) #NODE_303 was an open-label study designed to evaluate the safety & efficacy of etripamil across multiple episodes (up to 4⃣)
— cardio-met (@cardiomet_CE) March 30, 2025
of #PSVT; it was determined that sufficient data could be obtained by evaluating up to 4 episodes.
10c) If symptoms persisted, pts self-administered #etripamil 👃 70 mg. A repeat dose of etripamil 70 mg could be self-administered 10 min after the first dose. pic.twitter.com/cjIuNJm0nf
— cardio-met (@cardiomet_CE) March 30, 2025
12) Among the 151 pts who treated at least 2⃣ episodes, 108 (71.5%) successfully converted #PSVT ➡️#SR with etripamil by 60 min in the 1st episode, & of these, 87 (80.6%) converted with etripamil during their second episode (P=0.0019).
— cardio-met (@cardiomet_CE) March 30, 2025
14) An UNsuccessful conversion w/#etripamil during an earlier episode was NOT predictive of later lack of conversion. Of 43 pts who did not convert to #SR during their 1st episode, 24/43 (55.8%) still successfully converted #PSVT to SR during a subsequent etripamil-tx'd episode.
— cardio-met (@cardiomet_CE) March 30, 2025
16a) .@heartdrsingh summarizes the significance of these data for #HCPs who care for pts with #PSVT:
— cardio-met (@cardiomet_CE) March 30, 2025
1⃣ Very excited to soon have a therapy for our SVT patients that they can carry with them and safely administer !
17) And now you're caught up on the latest data for #PSVT mgt from #ACC25. Claim your 🆓 0.5hr CE/#CME certificate now at https://t.co/ulhUQUJrUm. And FOLLOW US for more #MedEd from ACC and afterwards. Thanks to expert faculty @heartdrsingh! #FOAMed #cardiotwitter
— cardio-met (@cardiomet_CE) March 30, 2025